金陵药业2024年净利下滑62%，董事长陈胜降薪、总裁陈海涨薪

Core Insights - Jinling Pharmaceutical (SZ000919) reported an increase in revenue but a significant decline in profit for the year 2024, indicating a challenging financial environment [1] Financial Performance - The total operating revenue for 2024 was 3.281 billion yuan, representing a year-on-year increase of 2.74% compared to 3.193 billion yuan in 2023 [2] - The net profit attributable to shareholders was 40.41 million yuan, a decrease of 61.95% from 106.19 million yuan in the previous year [2] - The net profit after deducting non-recurring gains and losses was 48.92 million yuan, down 40.44% from 82.14 million yuan in 2023 [2] - Cash flow from operating activities was 154.19 million yuan, reflecting a decline of 27.28% from 212.02 million yuan in 2023 [2] - Basic earnings per share were 0.0682 yuan, a drop of 67.63% from 0.2107 yuan in 2023 [2] Executive Compensation - Chairman Chen Sheng's salary for 2024 was 901,900 yuan, a decrease of 6.04% from the previous year [2] - President Chen Hai's salary increased to 950,200 yuan, a rise of 37.75% compared to 689,800 yuan in 2023 [2][4]